Technology Portfolio
Expanding
Westminster, CA – November 16, 2020 – BioLargo, Inc.
(OTCQB:BLGO), developer of sustainable technologies and a full-service
environmental engineering company, filed with the SEC its Quarterly Report on
Form 10-Q for the period ended September 30, 2020 (www.biolargo.com/sec-filings).
BioLargo’s Third Quarter Accomplishments
- Record revenue – generated record
revenues in the third quarter, rebounding from early pandemic shutdowns
- New business backlog – BioLargo’s industrial
operating divisions each have a backlog of revenue-generating projects that
collectively exceed $2 million, providing reliable revenue into 2021
- Advanced PFAS (“forever chemicals”) removal
technology – Refined the AEC water treatment technology, developed a
modular AEC unit, and have entered into substantial negotiations with a major
municipal water agency regarding a pilot project
- New CupriDyne formula – developed a new
CupriDyne formula and are preparing an application to register a product as a
sanitizer and hard-surface disinfectant with the US EPA
- Launched COVID product – our medical
subsidiary launched Clyraguard Personal Protective Spray on Amazon, and
expanded sales of Clyraguard from first quarter; it is launching a new product soon,
with another expected in mid to late 2021
- Developed a new technology – BioLargo engineers
invented a way to extract valuable minerals from certain types of industrial
waste, turning a customer’s liability into a billion-dollar revenue opportunity
while also creating a long-term revenue opportunity for BioLargo’s engineering
team
- Sales of odor and VOC control solutions to
Cannabis operators expanding – CupriDyne Clean odor control product’s use
is expanding in the Cannabis industry
- Municipal wastewater pilot under way –
began construction of a commercial-scale AOS water treatment system for
delivery to a municipal wastewater treatment plant in Montreal, Canada
- Improved balance sheet – retired over
$3.5 million in debt (by converting to equity), leaving approximately $1.1
million due in August of 2021 or later, and the remaining paid by Clyra
subsidiary from sales or as funds are available from financing efforts
BioLargo President and CEO Dennis P. Calvert commented,
“Several of our patented technologies are on the cusp of significant commercial
breakout. Our two water technologies – the AOS and the AEC – are now ready for
commercial trials that we believe will lead to first sales. We are constructing
our first commercial ready AOS unit now. At the same time, we are refining
comprehensive marketing plans for their rollout and are already in discussions
with customers, distributors and strategic partners.”
The company has
continually advanced its robust portfolio of technologies since it started this
journey in the spring of 2007. The technology portfolio has expanded to
include:
- PFAS removal
- SARS-CoV-2 solutions
- Infection control
- Wound management
- Regenerative tissue therapy
- Disinfection
- Air quality controls and systems including
odor and VOC control
- Water decontamination
- Micro-pollutant destruction and removal
- Legionella detection and water
treatment solutions
- Minerals processing
Calvert continued, “We have assembled world-class technologies and talent and are focused on
their highest and best purpose. While extraordinarily difficult, we have consistently
invested in R&D while advancing from technology to product and onto first
commercial sales and bundled services. We are now witnessing the first stages of
disruption, proving their opportunities for significant commercial futures. We
believe the value of our technology portfolio is far greater than is currently
reflected in our stock price and continue to march forward knowing that the
portfolio has a future that will generate value for decades to come. The
innovator’s journey is never easy, and there is no doubt that the
pandemic presented real additional challenges for BioLargo, but we are now in a
position where our balance sheet has dramatically improved, our revenues are
rebounding, and we have several potentially disruptive technologies ready to
launch into the marketplace. I was reminded recently by a highly trained
and accomplished innovator that, ‘solutions to some of the most important
challenges in the world LIVE at BioLargo’.
We agree and know it’s only a matter of time before we see their dramatic
impact around the world for a greater good.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and
environmental engineering solutions provider driven by a mission to “make life
better”. We feature unique disruptive
solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which
eliminates the odor-causing compounds and VOCs rather than masking them, and is
now winning over leading companies in the solid waste handling and wastewater
industries and other industries that contend with malodors and VOCs. Our
subsidiary BioLargo Water (www.biolargowater.ca) develops
the Advanced Oxidation System "AOS," a disruptive industrial water
treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and
technology licensor to our subsidiary Clyra Medical which features its
breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA
Registered, hospital grade disinfectant for personal protective equipment
including facemasks, proven 99.999% effective and safe for skin, as well as its
other products offering gentle solutions for chronic infected wounds to promote
infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
During the course of the stockholder
presentation, BioLargo may make “forward-looking statements” within the meaning
of the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995, regarding future events or the future financial
performance of the company that are subject to change. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
